Sugi Predict

Sugi Predict / Compounds / SCHEMBL186280

SCHEMBL186280

SCHEMBL186280

Nc1n[nH]c2cccc(Cl)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 1.00
▸ PDPK1 O15530 2/20 0.61
▸ MAP2K1 Q02750 2/20 0.56
▸ KDR P35968 5/20 0.54
▸ FLT3 P36888 2/20 0.54
▸ KIT P10721 1/20 0.54
▸ CHEK1 O14757 1/20 0.53
▸ PLK3 Q9H4B4 1/20 0.53
▸ JAK2 O60674 3/20 0.53
▸ JAK1 P23458 2/20 0.53
▸ TYK2 P29597 2/20 0.53
▸ JAK3 P52333 2/20 0.53
▸ LCK P06239 2/20 0.51
▸ CSF1R P07333 2/20 0.51
▸ FGFR1 P11362 2/20 0.51
▸ PRKACA P17612 2/20 0.51
▸ ROCK1 Q13464 2/20 0.51
▸ ABL1 P00519 2/20 0.51
▸ PLK4 O00444 1/20 0.51
▸ AURKA O14965 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16680480 0.84 GAA (0.72) GAAPDPK1MAP2K1KDRFLT3
SCHEMBL30065304 0.79 PDPK1 (0.66) GAAPDPK1MAP2K1KDRFLT3
SCHEMBL628649 0.79 PDPK1 (0.66) GAAPDPK1MAP2K1KDRFLT3
SCHEMBL7736987 0.76 PDPK1 (0.61) GAAPDPK1MAP2K1KDRFLT3
SCHEMBL569660 0.76 GAA (0.61) GAAPDPK1MAP2K1KDRFLT3
SCHEMBL185907 0.76 GAA (0.61) GAAPDPK1MAP2K1KDRFLT3
SCHEMBL10368038 0.76 PDPK1 (0.61) GAAPDPK1MAP2K1KDRFLT3
SCHEMBL30248298 0.76 GAA (0.61) GAAPDPK1MAP2K1KDRFLT3
SCHEMBL12928484 0.76 PDPK1 (0.61) GAAPDPK1MAP2K1KDRFLT3
SCHEMBL760018 0.76 PDPK1 (0.61) GAAPDPK1MAP2K1KDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101962365-A Aminoindazole derivatives as protein-kinase inhibitors AVENTIS PHARMA SA 2011-02-02 — — CN claimed
CN-1656078-A Aminoindazole derivatives as protein kinase inhibitors AVENTIS PHARMA SA (FR) 2005-08-17 — — CN claimed
US-20040014802-A1 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2004-01-22 — — US claimed
CN-119684214-A Preparation of 3-aminoindazole covalent compound and application thereof in treatment of parkinsonism 四川大学华西医院 2025-03-25 — — CN disclosed
CN-110818683-B 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof 中国科学院上海药物研究所 2023-04-14 — — CN disclosed
US-10668071-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-06-02 — — US disclosed
US-10668071-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-06-02 — — US disclosed
CN-110818683-A 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof 中国科学院上海药物研究所 2020-02-21 — — CN disclosed
EP-3066100-B1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS Bayer Pharma AG (DE) 2019-04-17 — — EP disclosed
EP-3066100-B1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS Bayer Pharma AG (DE) 2019-04-17 — — EP disclosed
US-20180344739-A1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-12-06 — — US disclosed
CN-1656078-A Aminoindazole derivatives as protein kinase inhibitors AVENTIS PHARMA SA (FR) 2005-08-17 — — CN disclosed
EP-1487804-A2 AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS Aventis Pharma S.A. (FR) 2004-12-22 — — EP disclosed
US-20040014802-A1 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2004-01-22 — — US disclosed
WO-2003078403-A2 DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE AVENTIS PHARMA S.A. (FR) 2003-09-25 — — WO disclosed
EP-0090972-B1 INDAZOLE DERIVATIVES Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1990-05-30 — — EP disclosed
US-4751302-A ANTIINFLAMMATORY, ANTIULCER AGENTS, ANALGESICS ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1988-06-14 — — US disclosed
US-4533731-A ANTIINFLAMMATORY AGENTS ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1985-08-06 — — US disclosed
EP-0090972-A2 Indazole derivatives Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1983-10-12 — — EP disclosed
US-4051252-A ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC BAYER AKTIENGESELLSCHAFT (DT) 1977-09-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014802-A1 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof CYP2C8, NR0B2, NR2C2 GAA 4778/4885PDPK1 4495/4885MAP2K1 4200/4885
US-20180344739-A1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE SERPINB6, SERPINC1, SERPINE1 GAA 3619/4885PDPK1 1304/4885MAP2K1 1165/4885
US-10668071-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use SERPINB6, SERPINC1, SERPINE1 GAA 3619/4885PDPK1 1304/4885MAP2K1 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.